重组人脑利钠肽治疗急性心肌梗死并左心功能不全患者的临床效果

摘要

目的：研究重组人脑利钠肽治疗急性心肌梗死并左心功能不全患者的临床效果。方法选取88例急性心肌梗死并左心功能不全的患者，按数字表法随机分为对照组和观察组，每组44例。在基础治疗的基础上对照组患者仅采用硝酸甘油进行治疗，观察组患者采用重组人脑利钠肽进行治疗。对比两组患者的治疗效果，治疗后不良反应的发生率和治疗前后尿量的变化。结果观察组患者治疗后总有效率（95．46％）明显高于对照组（65．91％）（P ＜0．05）；观察组治疗后不良反应的总发生率（11．36％）明显低于对照组治疗后不良反应的总发生率（59．09％）（P ＜0．05）；观察组患者治疗前后尿量差值（38．56±10．27）mL·h －1明显多于对照组（8．25±2．78）mL·h －1（P ＜0．05）。结论急性心肌梗死并左心功能不全患者采用重组人脑利钠肽治疗效果比硝酸甘油明显好转，不仅改善了患者的乏力、呼吸困难、液体潴留等临床症状，并且不良反应发生较少，增强了患者的治疗效果。%Objective To compare clinical effect of recombinant human brain natriuretic peptide and nitroglycerin in treatment of acute myocardial infarction patients with left ventricular dysfunction.Methods Eighty-eight cases of acute myocardial infarction patients with left ventricular dysfunction were assigned into the control group and the observation group,with 44 cases in each group.The patients of the control group were given only nitroglycerin treatment,while the patients of the observation group were treated with recombinant human brain natriuretic peptide.Therapeutic effect,incidence of adverse reactions after treatment and changes in urine volume before and after treatment in two groups were compared.Results After treatment the total efficiency rate of the observation group(95.46%) was significantly higher than the control group(65.91%),with statistically significant difference(P <0.05);overall adverse reactions incidence rate of the observation group(31.82%)was significantly lower than the control group(70.45%),with statistically significant difference(P <0.05);changes in urine volume of patients in the observation group [(38.56 ±10.27)mL·h -1 ]was significantly more than the control group [(8.25 ±2.78)mL·h -1 ],with statistically significant difference(P <0.05).Conclusions Recombinant human brain natriuretic peptide applied for treating acute myocardial infarction patients with left ventricular dysfunction was significantly better than nitroglycerin,which not only improves the patients’fatigue,difficulty in breathing,fluid retention and other symptoms,but also results in fewer adverse reactions and enhances clinical outcomes.